Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)

Next Previous
X
Search
Trial Profile

Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RDX 7675 (Primary)
  • Indications Hyperkalaemia; Kidney disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Nov 2017 According to a company media release, Ardelyx has made the decision to discontinue development of RDX7675, including both the onset-of-action and Phase 3 studies because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial.
    • 21 Nov 2017 Status changed from recruiting to discontinued according to an Ardelyx media release.
    • 07 Nov 2017 According to an Ardelyx media release, the company anticipates providing an update from the study by the end of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top